Morrison Chevaun D, Schiemann William P
Case Comprehensive Cancer Center, Case Western Reserve University, Wolstein Research Building, 2103 Cornell Road, Cleveland, OH, 44106, USA.
Breast Cancer Res. 2015 Jul 11;17:92. doi: 10.1186/s13058-015-0603-2.
Transforming growth factor beta (TGF-β) readily suppresses the development of early-stage breast cancers, an activity that gives way to tumor promotion in their late-stage counterparts. The molecular mechanisms underlying this mysterious switch in TGF-β function remain murky. In addressing this conundrum, Xu et al. observed aberrant 14-3-3ζ expression to prevent the formation of tumor-suppressive Smad2/3:p53 complexes, while simultaneously driving the generation of oncogenic Smad2/3:Gli2 complexes. Once formed, Smad2/3:Gli2 complexes stimulate the expression of parathyroid hormone-related protein necessary for breast cancer metastasis to bone. This viewpoint highlights 14-3-3ζ as an essential driver of oncogenic signaling by Smad2/3 and TGF-β in metastatic breast cancers.
转化生长因子β(TGF-β)很容易抑制早期乳腺癌的发展,而在晚期乳腺癌中,这种活性则转变为肿瘤促进作用。TGF-β功能这一神秘转变背后的分子机制仍不清楚。为了解决这个难题,徐等人观察到异常的14-3-3ζ表达会阻止肿瘤抑制性Smad2/3:p53复合物的形成,同时驱动致癌性Smad2/3:Gli2复合物的产生。一旦形成,Smad2/3:Gli2复合物会刺激乳腺癌转移至骨所必需的甲状旁腺激素相关蛋白的表达。这一观点突出了14-3-3ζ作为转移性乳腺癌中Smad2/3和TGF-β致癌信号的关键驱动因素。